Revvity
Revvity, Inc., formerly PerkinElmer, is an American life sciences and diagnostics company that provides reagents, cell analysis instruments, imaging systems, and specialized laboratory services globally. The company operates through two primary reporting business segments: Life Sciences and Diagnostics. Its principal revenue drivers stem from commercial sales of diagnostic assay kits, newborn screening systems, genomic reagents, image analysis hardware, and contract research services provided to pharmaceutical companies and clinical reference labs. Revvity holds a market-leading global position in newborn screening technologies, gene editing reagents, and drug discovery assay platforms, having rebranded from PerkinElmer following the divestiture of its legacy applied markets business. The enterprise serves global biopharmaceutical developers, healthcare providers, academic research institutions, and clinical laboratories. The company focuses on expanding gene therapy research tools, broadening oncology diagnostic assays, automating high-throughput screening platforms, and growing its global life sciences presence. Revvity, Inc. is headquartered in Waltham, Massachusetts, United States, and its common stock is publicly listed and traded on the New York Stock Exchange.
14 of the funds FundTelligence covers report a position in Revvity.
- Legal name
- Revvity Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 14
Funds holding Revvity
- SEB Nordamerikafond Små och Medelstora Bolag — SEB · 2.46 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.69 % (full portfolio disclosed, October 2026)
- Aktiespararna Global Direktavkastning — Cicero Fonder · 1.59 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 1.27 % (full portfolio disclosed, September 2026)
- Cicero Offensiv Hållbar — Cicero Fonder · 1.09 % (full portfolio disclosed, June 2026)
- Cicero Hållbar Mix — Cicero Fonder · 0.74 % (full portfolio disclosed, June 2026)
- Cicero Yield — Cicero Fonder · 0.35 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.17 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 14 funds holding it.